![]() | |
Clinical data | |
---|---|
Trade names | Bevyxxa, Dexxience, other |
Other names | PRT054021, PRT064445 |
AHFS/ Drugs.com | Monograph |
Routes of administration | By mouth |
Drug class | Anticoagulant ( direct factor Xa inhibitor) [1] |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 60% |
Elimination half-life | 19–27 hrs |
Duration of action | ≥72 hrs |
Excretion | 85% feces, 11% urine |
Identifiers | |
| |
Chemical and physical data | |
Formula | C23H22ClN5O3 |
Molar mass | 451.905 g·mol−1 |
3D model ( JSmol) | |
| |
| |
![]() ![]() |
Betrixaban, sold under the brand name Bevyxxa among others, was an anticoagulant used to prevent blood clots in veins in at risk adults, hospitalized for an illness. [2] It has a higher rate of bleeding compared to enoxaparin. [3] It was taken by mouth. [2]
Common side effects include bleeding. [1] Other side effects may include allergic reactions. [1] Safety in pregnancy is unclear. [1] It is a direct factor Xa inhibitor. [1]
Betrixaban was approved for medical use in the United States in 2017; however, has been subsequently discontinued. [1] It was refused approval in Europe in 2018 due to concerns regarding effectiveness and safety. [3]